Rickey Edward Carter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rickey Edward Carter has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Robert F. Woolson
3 shared publications- Andrew D. Siderowf2 shared publications
Bemard Ravina
2 shared publicationsBernard M. Ravina
2 shared publicationsBruce Levin
2 shared publicationsChangyong Feng
2 shared publications
Latest Publications
- 5 May 2012
- Published by Cambridge University Press (CUP)
- p. 147-159
Monitoring of Clinical Trials
This chapter highlights some important aspects of the design and analysis of clinical trials, and sketches a number of relevant statistical concepts. A controlled clinical trial of a medical intervention should have at least one primary hypothesis that drives its design. Well-designed and well-executed trials include an unambiguous protocol approved by the Institutional Review Boards (IRBs) or Ethics Committees of the participating clinics, laboratories, and data centers. The chapter also describes the basic frequentist statistical testing paradigm used by the typical randomized clinical trial with particular reference to ideas necessary in selecting sample size. Most clinical trials study more than one outcome of interest. Many neurological clinical trials compare therapies with respect to time to occurrence of the primary outcome. In the past, few clinical trials were performed in the Bayesian framework, but Bayesian methods have become more widely used recently.
- 5 May 2012
- Published by Cambridge University Press (CUP)
- p. 147-159
Monitoring of Clinical Trials
This chapter highlights some important aspects of the design and analysis of clinical trials, and sketches a number of relevant statistical concepts. A controlled clinical trial of a medical intervention should have at least one primary hypothesis that drives its design. Well-designed and well-executed trials include an unambiguous protocol approved by the Institutional Review Boards (IRBs) or Ethics Committees of the participating clinics, laboratories, and data centers. The chapter also describes the basic frequentist statistical testing paradigm used by the typical randomized clinical trial with particular reference to ideas necessary in selecting sample size. Most clinical trials study more than one outcome of interest. Many neurological clinical trials compare therapies with respect to time to occurrence of the primary outcome. In the past, few clinical trials were performed in the Bayesian framework, but Bayesian methods have become more widely used recently.
- 5 May 2012
- Published by Cambridge University Press (CUP)
Preface
Translating laboratory discoveries into successful therapeutics can be difficult. Clinical Trials in Neurology aims to improve the efficiency of clinical trials and the development of interventions in order to enhance the development of new treatments for neurologic diseases. It introduces the reader to the key concepts underpinning trials in the neurosciences. This volume tackles the challenges of developing therapies for neurologic disorders from measurement of agents in the nervous system to the progression of clinical signs and symptoms through illustrating specific study designs and their applications to different therapeutic areas. Clinical Trials in Neurology covers key issues in Phase I, II and III clinical trials, as well as post-marketing safety surveillance. Topics addressed include regulatory and implementation issues, outcome measures and common problems in drug development. Written by a multidisciplinary team, this comprehensive guide is essential reading for neurologists, psychiatrists, neurosurgeons, neuroscientists, statisticians and clinical researchers in the pharmaceutical industry.
- 5 May 2012
- Published by Cambridge University Press (CUP)
Preface
Translating laboratory discoveries into successful therapeutics can be difficult. Clinical Trials in Neurology aims to improve the efficiency of clinical trials and the development of interventions in order to enhance the development of new treatments for neurologic diseases. It introduces the reader to the key concepts underpinning trials in the neurosciences. This volume tackles the challenges of developing therapies for neurologic disorders from measurement of agents in the nervous system to the progression of clinical signs and symptoms through illustrating specific study designs and their applications to different therapeutic areas. Clinical Trials in Neurology covers key issues in Phase I, II and III clinical trials, as well as post-marketing safety surveillance. Topics addressed include regulatory and implementation issues, outcome measures and common problems in drug development. Written by a multidisciplinary team, this comprehensive guide is essential reading for neurologists, psychiatrists, neurosurgeons, neuroscientists, statisticians and clinical researchers in the pharmaceutical industry.
- 12 April 2012
- Published by Cambridge University Press (CUP)
Clinical Trials in Neurology
Translating laboratory discoveries into successful therapeutics can be difficult. Clinical Trials in Neurology aims to improve the efficiency of clinical trials and the development of interventions in order to enhance the development of new treatments for neurologic diseases. It introduces the reader to the key concepts underpinning trials in the neurosciences. This volume tackles the challenges of developing therapies for neurologic disorders from measurement of agents in the nervous system to the progression of clinical signs and symptoms through illustrating specific study designs and their applications to different therapeutic areas. Clinical Trials in Neurology covers key issues in Phase I, II and III clinical trials, as well as post-marketing safety surveillance. Topics addressed include regulatory and implementation issues, outcome measures and common problems in drug development. Written by a multidisciplinary team, this comprehensive guide is essential reading for neurologists, psychiatrists, neurosurgeons, neuroscientists, statisticians and clinical researchers in the pharmaceutical industry.
- 12 April 2012
- Published by Cambridge University Press (CUP)
Clinical Trials in Neurology
Translating laboratory discoveries into successful therapeutics can be difficult. Clinical Trials in Neurology aims to improve the efficiency of clinical trials and the development of interventions in order to enhance the development of new treatments for neurologic diseases. It introduces the reader to the key concepts underpinning trials in the neurosciences. This volume tackles the challenges of developing therapies for neurologic disorders from measurement of agents in the nervous system to the progression of clinical signs and symptoms through illustrating specific study designs and their applications to different therapeutic areas. Clinical Trials in Neurology covers key issues in Phase I, II and III clinical trials, as well as post-marketing safety surveillance. Topics addressed include regulatory and implementation issues, outcome measures and common problems in drug development. Written by a multidisciplinary team, this comprehensive guide is essential reading for neurologists, psychiatrists, neurosurgeons, neuroscientists, statisticians and clinical researchers in the pharmaceutical industry.
- Open Access
- 1 January 2008
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 34 (1) , 47-59
Improving the Transition from Residential to Outpatient Addiction Treatment: Gender Differences in Response to Supportive Telephone Calls
Substance use relapse rates are often high in the first months after discharge from inpatient substance abuse treatment, and patient adherence to aftercare plans is often low. Four residential addiction treatment centers participated in a feasibility study designed to estimate the efficacy of a post-discharge telephone intervention intended to encourage compliance with aftercare. A total of 282 participants (100 women, 182 men) with substance use disorders were included in this secondary analysis. The findings revealed that women were more likely than men to attend aftercare. This `gender effect' persisted after adjustment for a number of potential mediators.
- 1 January 2008
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 34 (1) , 47-59
Open AccessImproving the Transition from Residential to Outpatient Addiction Treatment: Gender Differences in Response to Supportive Telephone Calls
Substance use relapse rates are often high in the first months after discharge from inpatient substance abuse treatment, and patient adherence to aftercare plans is often low. Four residential addiction treatment centers participated in a feasibility study designed to estimate the efficacy of a post-discharge telephone intervention intended to encourage compliance with aftercare. A total of 282 participants (100 women, 182 men) with substance use disorders were included in this secondary analysis. The findings revealed that women were more likely than men to attend aftercare. This `gender effect' persisted after adjustment for a number of potential mediators.
- 1 October 2007
- Published by American Diabetes Association in Diabetes Care
- Vol. 30 (10) , 2646-2648
Intensive Treatment of Diabetes Is Associated With a Reduced Rate of Peripheral Arterial Calcification in The Diabetes Control and Complications Trial
Peripheral arterial disease (PAD) is a significant contributor to the morbidity and mortality of >2 million Americans (1). In addition to its own specific disease risks, PAD has been shown to be a predictor of cardiovascular mortality and coronary artery disease, as well as a general marker for the atherosclerotic disease process (2,3). PAD complications, especially in the lower limb, are significantly greater in individuals with diabetes compared with those without diabetes, and the risk imparted by diabetes is similar or greater in magnitude to that seen for ischemic heart disease and stroke (4,5). The aortofemoral arteries are prime sites for PAD; hence, determination of claudication and measurement of blood flow in the lower extremities are the most common assessments (6). A relatively low ankle systolic blood pressure (ankle-to-brachial ratio index [ABI]) has been found to be an indicator of atherosclerosis/occlusion in this region (5). Conversely, in diabetes, a high-pressure ABI due to medial wall arterial calcification and noncompressible vessels may also be associated with adverse outcomes, including diabetic kidney disease (7). Sex differences have been reported in ABI measurements in type 1 diabetes, with women having a greater frequency of low ABI and men having a higher frequency of high ABI (7). Here, we extend these analyses by examining the effect of previous intensive diabetes management on the development of abnormally high and low ABIs in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) cohort with the hypothesis that …
- 1 October 2007
- Published by American Diabetes Association in Diabetes Care
- Vol. 30 (10) , 2646-2648
Intensive Treatment of Diabetes Is Associated With a Reduced Rate of Peripheral Arterial Calcification in The Diabetes Control and Complications Trial
Peripheral arterial disease (PAD) is a significant contributor to the morbidity and mortality of >2 million Americans (1). In addition to its own specific disease risks, PAD has been shown to be a predictor of cardiovascular mortality and coronary artery disease, as well as a general marker for the atherosclerotic disease process (2,3). PAD complications, especially in the lower limb, are significantly greater in individuals with diabetes compared with those without diabetes, and the risk imparted by diabetes is similar or greater in magnitude to that seen for ischemic heart disease and stroke (4,5). The aortofemoral arteries are prime sites for PAD; hence, determination of claudication and measurement of blood flow in the lower extremities are the most common assessments (6). A relatively low ankle systolic blood pressure (ankle-to-brachial ratio index [ABI]) has been found to be an indicator of atherosclerosis/occlusion in this region (5). Conversely, in diabetes, a high-pressure ABI due to medial wall arterial calcification and noncompressible vessels may also be associated with adverse outcomes, including diabetic kidney disease (7). Sex differences have been reported in ABI measurements in type 1 diabetes, with women having a greater frequency of low ABI and men having a higher frequency of high ABI (7). Here, we extend these analyses by examining the effect of previous intensive diabetes management on the development of abnormally high and low ABIs in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) cohort with the hypothesis that …
- 29 November 2006
- Published by Oxford University Press (OUP) in Journal of the Royal Statistical Society Series A: Statistics in Society
- Vol. 170 (1) , 185-193
Estimating The Variance of Estimated Trends in Proportions When There is No Unique Subject Identifier
Summary: Longitudinal population-based surveys are widely used in the health sciences to study patterns of change over time. In many of these data sets unique patient identifiers are not publicly available, making it impossible to link the repeated measures from the same individual directly. This poses a statistical challenge for making inferences about time trends because repeated measures from the same individual are likely to be positively correlated, i.e., although the time trend that is estimated under the naïve assumption of independence is unbiased, an unbiased estimate of the variance cannot be obtained without knowledge of the subject identifiers linking repeated measures over time. We propose a simple method for obtaining a conservative estimate of variability for making inferences about trends in proportions over time, ensuring that the type I error is no greater than the specified level. The method proposed is illustrated by using longitudinal data on diabetes hospitalization proportions in South Carolina.
- 29 November 2006
- Published by Oxford University Press (OUP) in Journal of the Royal Statistical Society Series A: Statistics in Society
- Vol. 170 (1) , 185-193
Estimating The Variance of Estimated Trends in Proportions When There is No Unique Subject Identifier
Summary: Longitudinal population-based surveys are widely used in the health sciences to study patterns of change over time. In many of these data sets unique patient identifiers are not publicly available, making it impossible to link the repeated measures from the same individual directly. This poses a statistical challenge for making inferences about time trends because repeated measures from the same individual are likely to be positively correlated, i.e., although the time trend that is estimated under the naïve assumption of independence is unbiased, an unbiased estimate of the variance cannot be obtained without knowledge of the subject identifiers linking repeated measures over time. We propose a simple method for obtaining a conservative estimate of variability for making inferences about trends in proportions over time, ensuring that the type I error is no greater than the specified level. The method proposed is illustrated by using longitudinal data on diabetes hospitalization proportions in South Carolina.
- Open Access
- 30 March 2005
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 5 (1) , 11
Practical considerations for estimating clinical trial accrual periods: application to a multi-center effectiveness study
Background: Adequate participant recruitment is vital to the conduct of a clinical trial. Projected recruitment rates are often over-estimated, and the time to recruit the target population (accrual period) is often under-estimated. Methods: This report illustrates three approaches to estimating the accrual period and applies the methods to a multi-center, randomized, placebo controlled trial undergoing development. Results: Incorporating known sources of accrual variation can yield a more justified estimate of the accrual period. Simulation studies can be incorporated into a clinical trial's planning phase to provide estimates for key accrual summaries including the mean and standard deviation of the accrual period. Conclusion: The accrual period of a clinical trial should be carefully considered, and the allocation of sufficient time for participant recruitment is a fundamental aspect of planning a clinical trial.
- 30 March 2005
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 5 (1) , 11
Open AccessPractical considerations for estimating clinical trial accrual periods: application to a multi-center effectiveness study
Background: Adequate participant recruitment is vital to the conduct of a clinical trial. Projected recruitment rates are often over-estimated, and the time to recruit the target population (accrual period) is often under-estimated. Methods: This report illustrates three approaches to estimating the accrual period and applies the methods to a multi-center, randomized, placebo controlled trial undergoing development. Results: Incorporating known sources of accrual variation can yield a more justified estimate of the accrual period. Simulation studies can be incorporated into a clinical trial's planning phase to provide estimates for key accrual summaries including the mean and standard deviation of the accrual period. Conclusion: The accrual period of a clinical trial should be carefully considered, and the allocation of sufficient time for participant recruitment is a fundamental aspect of planning a clinical trial.
- Open Access
- 13 January 2005
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 5 (1) , 3
Systems validation: application to statistical programs
Background: In 2003, the United States Food and Drug Administration (FDA) released a guidance document on the scope of "Part 11" enforcement. In this guidance document, the FDA indicates an expectation of a risk-based approach to determining which systems should undergo validation. Since statistical programs manage and manipulate raw data, their implementation should be critically reviewed to determine whether or not they should undergo validation. However, the concepts of validation are not often discussed in biostatistics curriculum. Discussion: This paper summarizes a "Plan, Do, Say" approach to validation that can be incorporated into statistical training so that biostatisticians can understand and implement validation principles in their research. Summary: Validation is a process that requires dedicated attention. The process of validation can be easily understood in the context of the scientific method.
- 13 January 2005
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 5 (1) , 3
Open AccessSystems validation: application to statistical programs
Background: In 2003, the United States Food and Drug Administration (FDA) released a guidance document on the scope of "Part 11" enforcement. In this guidance document, the FDA indicates an expectation of a risk-based approach to determining which systems should undergo validation. Since statistical programs manage and manipulate raw data, their implementation should be critically reviewed to determine whether or not they should undergo validation. However, the concepts of validation are not often discussed in biostatistics curriculum. Discussion: This paper summarizes a "Plan, Do, Say" approach to validation that can be incorporated into statistical training so that biostatisticians can understand and implement validation principles in their research. Summary: Validation is a process that requires dedicated attention. The process of validation can be easily understood in the context of the scientific method.
- Open Access
- 23 December 2004
- Published by Oxford University Press (OUP) in Biostatistics
- Vol. 6 (1) , 39-44
Quasi-likelihood estimation for relative risk regression models
For a prospective randomized clinical trial with two groups, the relative risk can be used as a measure of treatment effect and is directly interpretable as the ratio of success probabilities in the new treatment group versus the placebo group. For a prospective study with many covariates and a binary outcome (success or failure), relative risk regression may be of interest. If we model the log of the success probability as a linear function of covariates, the regression coefficients are log-relative risks. However, using such a log–linear model with a Bernoulli likelihood can lead to convergence problems in the Newton–Raphson algorithm. This is likely to occur when the success probabilities are close to one. A constrained likelihood method proposed by Wacholder (1986, American Journal of Epidemiology123, 174–184), also has convergence problems. We propose a quasi-likelihood method of moments technique in which we naively assume the Bernoulli outcome is Poisson, with the mean (success probability) following a log–linear model. We use the Poisson maximum likelihood equations to estimate the regression coefficients without constraints. Using method of moment ideas, one can show that the estimates using the Poisson likelihood will be consistent and asymptotically normal. We apply these methods to a double-blinded randomized trial in primary biliary cirrhosis of the liver (Markus et al., 1989, New England Journal of Medicine320, 1709–1713).
- 23 December 2004
- Published by Oxford University Press (OUP) in Biostatistics
- Vol. 6 (1) , 39-44
Open AccessQuasi-likelihood estimation for relative risk regression models
For a prospective randomized clinical trial with two groups, the relative risk can be used as a measure of treatment effect and is directly interpretable as the ratio of success probabilities in the new treatment group versus the placebo group. For a prospective study with many covariates and a binary outcome (success or failure), relative risk regression may be of interest. If we model the log of the success probability as a linear function of covariates, the regression coefficients are log-relative risks. However, using such a log–linear model with a Bernoulli likelihood can lead to convergence problems in the Newton–Raphson algorithm. This is likely to occur when the success probabilities are close to one. A constrained likelihood method proposed by Wacholder (1986, American Journal of Epidemiology123, 174–184), also has convergence problems. We propose a quasi-likelihood method of moments technique in which we naively assume the Bernoulli outcome is Poisson, with the mean (success probability) following a log–linear model. We use the Poisson maximum likelihood equations to estimate the regression coefficients without constraints. Using method of moment ideas, one can show that the estimates using the Poisson likelihood will be consistent and asymptotically normal. We apply these methods to a double-blinded randomized trial in primary biliary cirrhosis of the liver (Markus et al., 1989, New England Journal of Medicine320, 1709–1713).
- 15 December 2004
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 6 (6) , 234-238
Alzheimer's Disease in the Family Practice Setting
BACKGROUND: The prevalence of Alzheimer's disease (AD) is approximately 4.5 million people in the United States, and it is projected that by 2050, the prevalence could be as high as 16 million. As one step to minimize this health care burden, we investigated the practices of primary care physicians (PCPs) to determine barriers to and incentives in diagnosing AD and assessed the feasibility of utilizing a caregiver-based phone interview for dementia in the primary care setting. METHOD: This feasibility study was conducted in 2 phases. Phase I included PCP focus groups conducted to identify barriers and incentives to diagnosis of Alzheimer's disease, knowledge of available screening instruments, and current diagnostic procedures and patterns. A survey of a random sample of PCPs was also conducted to reassess the data obtained via the focus groups. Phase II assessed the feasibility of implementing a brief, caregiver-based dementia screening tool in the primary care setting. A participant's score on the screening tool was compared with the PCP's clinical impression using the kappa statistic. RESULTS: A general willingness exists among PCPs to improve the level of care for patients with AD; however, time constraints are a sizeable barrier in the PCP setting. The incorporation of a telephone-based (or caregiver-based) assessment is feasible. The agreement between the caregiver ratings and the PCPs' clinical impressions was kappa = 0.64 (95% CI = 0.19 to 1.0). CONCLUSION: The caregiver-based telephone assessment has indications of good agreement with the PCP's general assessment of dementia or possible AD. The limited number of patients with positive screens hinders generalization of this phase of the study, but the results confirm the potential value of caregiver-based assessment and the desirability of a larger study to address the scientific properties of a telephone-based screening instrument.
- 15 December 2004
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 6 (6) , 234-238
Alzheimer's Disease in the Family Practice Setting
BACKGROUND: The prevalence of Alzheimer's disease (AD) is approximately 4.5 million people in the United States, and it is projected that by 2050, the prevalence could be as high as 16 million. As one step to minimize this health care burden, we investigated the practices of primary care physicians (PCPs) to determine barriers to and incentives in diagnosing AD and assessed the feasibility of utilizing a caregiver-based phone interview for dementia in the primary care setting. METHOD: This feasibility study was conducted in 2 phases. Phase I included PCP focus groups conducted to identify barriers and incentives to diagnosis of Alzheimer's disease, knowledge of available screening instruments, and current diagnostic procedures and patterns. A survey of a random sample of PCPs was also conducted to reassess the data obtained via the focus groups. Phase II assessed the feasibility of implementing a brief, caregiver-based dementia screening tool in the primary care setting. A participant's score on the screening tool was compared with the PCP's clinical impression using the kappa statistic. RESULTS: A general willingness exists among PCPs to improve the level of care for patients with AD; however, time constraints are a sizeable barrier in the PCP setting. The incorporation of a telephone-based (or caregiver-based) assessment is feasible. The agreement between the caregiver ratings and the PCPs' clinical impressions was kappa = 0.64 (95% CI = 0.19 to 1.0). CONCLUSION: The caregiver-based telephone assessment has indications of good agreement with the PCP's general assessment of dementia or possible AD. The limited number of patients with positive screens hinders generalization of this phase of the study, but the results confirm the potential value of caregiver-based assessment and the desirability of a larger study to address the scientific properties of a telephone-based screening instrument.